The next step from high-flux dialysis: Application of sorbent technology

James F. Winchester, Claudio Ronco, James A. Brady, Larry D Cowgill, Jamie Salsberg, Eric Yousha, Mike Choquette, Robert Albright, Jonathan Clemmer, Vadim Davankov, Maria Tsyurupa, Ludmila Pavlova, Mikhail Pavlov, Gerald Cohen, Walter Hörl, Frank Gotch, Nathan W. Levin

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The current foci of renal replacement therapy with dialysis are middle molecular weight toxins, consisting of small proteins, polypeptides and products of glycosylation and lipoxygenation. Conventional high-flux dialysis is not efficient at removing these molecules, explaining the increased interest in using sorbents to supplement dialysis techniques. Prototype biocompatible sorbents have been developed and investigated for middle molecule removal; these have been shown, in man, to remove β2-microglobulin, angiogenin, leptin, cytokines and other molecules, without reducing platelets and leukocytes. Extensive clinical studies are underway to demonstrate the clinical utility and safety of adding routinely a sorbent hemoperfusion device to hemodialysis.

Original languageEnglish (US)
Pages (from-to)81-86
Number of pages6
JournalBlood Purification
Volume20
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Dialysis
Technology
Hemoperfusion
Renal Replacement Therapy
Leptin
Glycosylation
Renal Dialysis
Leukocytes
Blood Platelets
Molecular Weight
Cytokines
Safety
Equipment and Supplies
Peptides
Proteins
Clinical Studies
angiogenin

Keywords

  • β2-Microglobulin
  • Adsorption
  • Angiogenin
  • Biocompatibility
  • Cytokines
  • Hemoperfusion
  • Leptin
  • Sorbents

ASJC Scopus subject areas

  • Nephrology
  • Hematology

Cite this

Winchester, J. F., Ronco, C., Brady, J. A., Cowgill, L. D., Salsberg, J., Yousha, E., ... Levin, N. W. (2002). The next step from high-flux dialysis: Application of sorbent technology. Blood Purification, 20(1), 81-86. https://doi.org/10.1159/000046989

The next step from high-flux dialysis : Application of sorbent technology. / Winchester, James F.; Ronco, Claudio; Brady, James A.; Cowgill, Larry D; Salsberg, Jamie; Yousha, Eric; Choquette, Mike; Albright, Robert; Clemmer, Jonathan; Davankov, Vadim; Tsyurupa, Maria; Pavlova, Ludmila; Pavlov, Mikhail; Cohen, Gerald; Hörl, Walter; Gotch, Frank; Levin, Nathan W.

In: Blood Purification, Vol. 20, No. 1, 2002, p. 81-86.

Research output: Contribution to journalArticle

Winchester, JF, Ronco, C, Brady, JA, Cowgill, LD, Salsberg, J, Yousha, E, Choquette, M, Albright, R, Clemmer, J, Davankov, V, Tsyurupa, M, Pavlova, L, Pavlov, M, Cohen, G, Hörl, W, Gotch, F & Levin, NW 2002, 'The next step from high-flux dialysis: Application of sorbent technology', Blood Purification, vol. 20, no. 1, pp. 81-86. https://doi.org/10.1159/000046989
Winchester, James F. ; Ronco, Claudio ; Brady, James A. ; Cowgill, Larry D ; Salsberg, Jamie ; Yousha, Eric ; Choquette, Mike ; Albright, Robert ; Clemmer, Jonathan ; Davankov, Vadim ; Tsyurupa, Maria ; Pavlova, Ludmila ; Pavlov, Mikhail ; Cohen, Gerald ; Hörl, Walter ; Gotch, Frank ; Levin, Nathan W. / The next step from high-flux dialysis : Application of sorbent technology. In: Blood Purification. 2002 ; Vol. 20, No. 1. pp. 81-86.
@article{9b353f43562948e98aa50676eefb8bdf,
title = "The next step from high-flux dialysis: Application of sorbent technology",
abstract = "The current foci of renal replacement therapy with dialysis are middle molecular weight toxins, consisting of small proteins, polypeptides and products of glycosylation and lipoxygenation. Conventional high-flux dialysis is not efficient at removing these molecules, explaining the increased interest in using sorbents to supplement dialysis techniques. Prototype biocompatible sorbents have been developed and investigated for middle molecule removal; these have been shown, in man, to remove β2-microglobulin, angiogenin, leptin, cytokines and other molecules, without reducing platelets and leukocytes. Extensive clinical studies are underway to demonstrate the clinical utility and safety of adding routinely a sorbent hemoperfusion device to hemodialysis.",
keywords = "β2-Microglobulin, Adsorption, Angiogenin, Biocompatibility, Cytokines, Hemoperfusion, Leptin, Sorbents",
author = "Winchester, {James F.} and Claudio Ronco and Brady, {James A.} and Cowgill, {Larry D} and Jamie Salsberg and Eric Yousha and Mike Choquette and Robert Albright and Jonathan Clemmer and Vadim Davankov and Maria Tsyurupa and Ludmila Pavlova and Mikhail Pavlov and Gerald Cohen and Walter H{\"o}rl and Frank Gotch and Levin, {Nathan W.}",
year = "2002",
doi = "10.1159/000046989",
language = "English (US)",
volume = "20",
pages = "81--86",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - The next step from high-flux dialysis

T2 - Application of sorbent technology

AU - Winchester, James F.

AU - Ronco, Claudio

AU - Brady, James A.

AU - Cowgill, Larry D

AU - Salsberg, Jamie

AU - Yousha, Eric

AU - Choquette, Mike

AU - Albright, Robert

AU - Clemmer, Jonathan

AU - Davankov, Vadim

AU - Tsyurupa, Maria

AU - Pavlova, Ludmila

AU - Pavlov, Mikhail

AU - Cohen, Gerald

AU - Hörl, Walter

AU - Gotch, Frank

AU - Levin, Nathan W.

PY - 2002

Y1 - 2002

N2 - The current foci of renal replacement therapy with dialysis are middle molecular weight toxins, consisting of small proteins, polypeptides and products of glycosylation and lipoxygenation. Conventional high-flux dialysis is not efficient at removing these molecules, explaining the increased interest in using sorbents to supplement dialysis techniques. Prototype biocompatible sorbents have been developed and investigated for middle molecule removal; these have been shown, in man, to remove β2-microglobulin, angiogenin, leptin, cytokines and other molecules, without reducing platelets and leukocytes. Extensive clinical studies are underway to demonstrate the clinical utility and safety of adding routinely a sorbent hemoperfusion device to hemodialysis.

AB - The current foci of renal replacement therapy with dialysis are middle molecular weight toxins, consisting of small proteins, polypeptides and products of glycosylation and lipoxygenation. Conventional high-flux dialysis is not efficient at removing these molecules, explaining the increased interest in using sorbents to supplement dialysis techniques. Prototype biocompatible sorbents have been developed and investigated for middle molecule removal; these have been shown, in man, to remove β2-microglobulin, angiogenin, leptin, cytokines and other molecules, without reducing platelets and leukocytes. Extensive clinical studies are underway to demonstrate the clinical utility and safety of adding routinely a sorbent hemoperfusion device to hemodialysis.

KW - β2-Microglobulin

KW - Adsorption

KW - Angiogenin

KW - Biocompatibility

KW - Cytokines

KW - Hemoperfusion

KW - Leptin

KW - Sorbents

UR - http://www.scopus.com/inward/record.url?scp=0036007329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036007329&partnerID=8YFLogxK

U2 - 10.1159/000046989

DO - 10.1159/000046989

M3 - Article

C2 - 11803163

AN - SCOPUS:0036007329

VL - 20

SP - 81

EP - 86

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 1

ER -